Nightstar Therapeutics Company
Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.
Technology:
Neurological Disorders
Estimated Revenue:
$1M to $10M
Founded Date:
2013
Total Funding:
$174.6M
Investor Type:
Company
Headquarters:
London, England, United Kingdom
Funding Status:
M&A
Last Funding Type:
Post-IPO Equity
Employee Number:
11-50
Number Of Exists:
Post-IPO Equity
Industry:
Gene Therapy
Investment Stage:
N/A
Investors Number:
4